Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926576 | 0.86 | HPGD (0.61) | RAB9AKMT2AALDH1A1HPGDCCR3 | |
| SCHEMBL9926647 | 0.76 | CCR3 (0.62) | CCR3 | |
| SCHEMBL9926516 | 0.76 | POLB (0.60) | KMT2AALDH1A1 | |
| SCHEMBL24352145 | 0.76 | KMT2A (0.72) | RAB9AAKR1C3KMT2AFKBP1AALDH1A1 | |
| SCHEMBL11961573 | 0.75 | KDM4E (0.53) | RAB9AKMT2AFKBP1AKDM4EALDH1A1 | |
| SCHEMBL4243681 | 0.75 | CYP2A13 (0.71) | RAB9AKMT2AKDM4ETDP1 | |
| SCHEMBL9557026 | 0.74 | NAAA (0.61) | RAB9AAKR1C3KMT2AKDM4EALDH1A1 | |
| SCHEMBL4719668 | 0.74 | MGLL (0.68) | RAB9AAKR1C3KMT2AFKBP1AKDM4E | |
| SCHEMBL20886966 | 0.72 | KMT2A (0.58) | RAB9AAKR1C3KMT2AFKBP1AKDM4E | |
| SCHEMBL13342919 | 0.72 | RAB9A (0.62) | RAB9AAKR1C3KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | RAB9A 3018/4885AKR1C3 2183/4885KMT2A 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.